Monday, January 28

• Verizon Communications (NYSE: VZ) is reporting Q4 earnings; conference call at 8:30am.
• Halliburton Company (NYSE: HAL) is reporting Q4 earnings; conference call at 9am.
• Compass Diversified Holdings (NASDAQ: CODI) to hold conference call to discuss the acquisition of Staffmark Investment & Fox Factory.
• Warner Chilcott Ltd. (NASDAQ: WCRX) to hold conference call to give 2008 guidance.

Tuesday, January 29

• PDUFA date for GlaxoSmithKline plc (ADR) (NYSE: GSK)'s Cervarix, a cervical cancer vaccine.
• JetBlue Airways Corporation (NASDAQ: JBLU) to report Q4 earnings; conference call at 10:00am.
• United States Steel Corporation (NYSE: X) to report Q4 earnings; conference call at 3:00pm.
• Yahoo! Inc. (NASDAQ: YHOO) to report Q4 earnings; conference call at 5:00pm.

Wednesday, January 30

• PDUFA date for Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and Wyeth (NYSE: WYE)' Methylanaltrexone, an opioid receptor antagonists for treatment of opioid-induced constipation.
• PDUFA date for Lev Pharmaceuticals, Inc. (OTC: LEVP)'s Cinryze for acute HAE.
• Boeing Inc. (NYSE: BA) to report Q4 earnings; conference call at 10:30am.
• Altria (NYSE: MO) to report Q4 earnings; conference call at 1:00pm.
• Starbucks (NASDAQ: SBUX) to report Q1 earnings; conference call at 5:00pm.

Thursday, January 31

• Google, Inc. (NASDAQ: GOOG) to report Q4 earnings; conference call at 4:30pm.

Friday, February 1

• Exxon Mobil Corporation (NYSE: XOM) to report Q4 earnings; conference call at 11:00am.
• PDUFA date for Axcan Pharma Inc. (NASDAQ: AXCA)'s for Ultrase/Ultrase MT (Pancrelipase) enzyme replacement therapy for treatment of chronic Pancreatitis and Pancreatic Deficiency related to Cystic Fibrosis.

For some companies, focusing on a single specialization is the best way to build a reputation, leverage resources and maximize effectiveness. There is a Mont-Saint-Hilaire, Quebec outfit that has followed that path to leadership in the field of gastroenterology-related pharmaceuticals.

Axcan Pharma (NASDAQ: AXCA) is engaged in the development and sale of pharmaceutical products for the treatment of gastrointestinal diseases and disorders. Products include medicines for exocrine pancreatic insufficiency diseases; cholestatic liver diseases; inflammatory bowel diseases; gastric duodenal ulcers; and irritable bowel syndrome. The firm also owns the global rights to Photofrin, a drug with applications to esophageal, gastric and lung cancers. Other products include caloric supplements for cystic fibrosis patients and over-the-counter antacids. The company sells its products primarily to wholesale drug companies and distributors. Novartis (NYSE: NVS) is a major competitor.

The firm pleased investors last week, when it reported fiscal Q3 EPS of 36 cents and revenues of $92.3 million. Analysts had been expecting 26 cents and $81.6 million. Management also guided FY07 revenues to $335-$343 million, versus Street consensus of $324.74 million.